Department of Gynecology, Gynecological Endocrinology and Oncology, Philipps-University of Marburg, Baldingerstrasse, 35043, Marburg, Germany.
J Cancer Res Clin Oncol. 2013 Jun;139(6):915-23. doi: 10.1007/s00432-013-1402-8. Epub 2013 Feb 27.
Adjuvant treatment for hormone receptor-positive breast cancer in postmenopausal women with aromatase inhibitors is associated with increased bone loss depending on the compliance to treatment.
In this bone substudy, bone mineral density (BMD) was assessed by dual energy X-ray absorptiometry at baseline and after 12- and 24-month treatment in 63 patients receiving Anastrozole as adjuvant treatment for hormone receptor-positive early breast cancer. To minimize the effects of confounders, a matched pair analysis (compliant N = 21, non-compliant N = 21) was performed.
Anastrozole treatment in compliant patients leads to a decrease in BMD (g/cm(2)) at lumbar spine and total hip from baseline to 12 and 24 months (-2.57 % P = 0.004; -2.02 % P = 0.05; -2.57 % P = 0.001 and -4.18 % P = 0.003, respectively) compared to non-compliant patients (-1.71 % P = 0.050; -2.00 % P = 0.085; -1.65 % P = 0.055 and -3.20 % P = 0.005, respectively).
Anastrozole treatment in compliant patients with breast cancer resulted in a larger, increase in bone loss at 12 and 24 months compared to non-compliant patients. Bone loss stabilized in both groups at the spine from 12- to 24-month treatment, whereas maintained at the total hip.
芳香化酶抑制剂用于绝经后激素受体阳性乳腺癌的辅助治疗与骨丢失增加有关，具体取决于对治疗的依从性。
在这项骨亚研究中，对 63 例接受阿那曲唑作为激素受体阳性早期乳腺癌辅助治疗的患者，在基线时和治疗 12 个月和 24 个月后使用双能 X 线吸收法评估骨密度（BMD）。为了最小化混杂因素的影响，进行了匹配对分析（依从性 N=21，不依从性 N=21）。
在依从性患者中，阿那曲唑治疗导致腰椎和全髋骨密度（g/cm(2)）从基线到 12 个月和 24 个月时下降（-2.57%，P=0.004；-2.02%，P=0.05；-2.57%，P=0.001 和-4.18%，P=0.003），而不依从性患者则下降（-1.71%，P=0.050；-2.00%，P=0.085；-1.65%，P=0.055 和-3.20%，P=0.005）。
与不依从性患者相比，在依从性患者中，阿那曲唑治疗导致乳腺癌患者在 12 个月和 24 个月时的骨丢失增加更大。在两组中，从 12 个月到 24 个月的治疗期间，脊柱的骨丢失稳定，而全髋的骨丢失则保持不变。
